Valvoline’s Q2 Results Highlight Sales Increase, Stock Surges Higher

Valvoline Inc (NYSE:VVV) reported second-quarter FY23 sales growth of 16% year-on-year to $344.50 million, marginally beating the analyst consensus of…
  • Valvoline Inc (NYSE:VVV) reported second-quarter FY23 sales growth of 16% year-on-year to $344.50 million, marginally beating the analyst consensus of $344.36 million.
  • The automotive services provider registered an adjusted EPS of $0.23, missing the analyst consensus of $0.28.
  • System-wide SSS increased 13.5% Y/Y.
  • Gross profit climbed 18.1% to $126.7 million, with a profit margin of 36.8%.
  • Operating income for the quarter jumped 53% to $61.2 million, with a margin of 17.8%.
  • At quarter end, Cash and cash equivalents balance was $2.3 billion, with $8.3 million of interest income earned on net proceeds from the sale of Global Products.
  • “As we approach the summer travel season, our stores are well staffed and prepared to continue driving growth in the back half of the year,” said CEO Sam Mitchell.
  • Outlook: Valvoline reiterated its FY23 outlook. Valvoline sees FY23 System-wide SSS growth of 8% – 12%.
  • The company expects FY23 revenue of $1.4 billion – $1.5 billion (consensus at $1.43 billion) and adjusted EBITDA of $370 million – $390 million.
  • Price Action: VVV shares are trading higher by 12.5% at $38.57 on the last check Wednesday.

Now Read: Disney Q2 Earnings Preview: Analyst Estimates, Disney+ Versus Rivals, Dividend Talk, DeSantis Battle And More

Photo: Shutterstock

 

Total
0
Shares
Related Posts
Read More

Exclusive: Historic Importation Of THC Into The US Could Reshape Global Cannabis Supply Chain

This novel venture could reshape the foundations of the global medical cannabis supply by delivering alternative THC products to a DEA-approved Schedule 1 lab in the U.S and providing universities, researchers and pharmaceutical entities with an alternative to the University of Mississippi, which until very recently had been the sole legal supplier of THC active pharmaceutical in

BGXX